Familial Endocrine Cancer Syndromes
Springer International Publishing (Verlag)
978-3-031-37274-2 (ISBN)
This book is composed of 13 informative chapters written by world-renowned healthcare providers and researchers in the fields of endocrinology, pharmacy, radiology, infertility, pediatrics, internal medicine, psychology and genetics. From topics covering psychosocial impacts to pharmacokinetic and homecare resources, the intent of this book is to provide guiding principles for a safe and informative transition of care for pediatric and adolescent patients with various familial endocrine cancer syndromes that are transitioning from pediatric to adult health care. It provides an in-depth exploration of the diagnostic and therapeutic strategies, survivorship navigation intervention, patient, caregiver and primary care provider challenges, and multidisciplinary care plans for conditions such as MEN1, MEN2 and other familial and genetic endocrine neoplasias.
Familial Endocrine Cancer Syndromes: Navigating the Transition of Care for Pediatric and Adolescent Patients is a much-needed resource, as the literature currently lacks a comprehensive publication to facilitate pediatric patients' transition to adult clinics and resources following endocrine cancer diagnosis and treatment.
lt;p>Fady Hannah-Shmouni, MD ABIM FRCPC is a physician-entrepreneur specializing in internal medicine, neuroendocrinology and genetics, and early-stage investments and advisory in medtech, biotech, and blockchain companies. Dr. Shmouni completed clinical training in internal medicine at Yale School of Medicine; adult endocrinology, diabetes and metabolism at the National Institutes of Health, America's research hospital, under the mentorship of Constantine A. Stratakis; and clinical biochemical genetics at the University of Toronto. He is board-certified in internal medicine and endocrinology by the American Board of Internal Medicine and Royal College of Physician and Surgeons of Canada; and in clinical hypertension by the American Society of Hypertension.
During his tenure at NIH (2015-2021), Dr. Shmouni was the Director of Graduate Medical Education, Associate Program Director of the Inter-Institute Endocrinology Fellowship Program, and Primary Investigator on several genetic and adrenal related research protocols. His clinical and research focus was on the evaluation of patients with various inherited metabolic and endocrine conditions, including endocrine cancer predisposition syndromes, and was the Co-Chief of the outpatient endocrine clinic, where he oversaw the clinical management of patients with Carney complex, cushing syndrome, acromegaly, multiple endocrine neoplasia, and various inborn errors of metabolism.
Dr. Shmouni is a passionate clinician and advocate for rare diseases. He is a professor and staff physician at Vancouver General Hospital (University of British Columbia), practicing endocrinology and internal medicine. He is a fellow with the Royal College of Physicians and Surgeons of Canada and an active committee member of the Endocrine Society, International Society of Hypertension, Hypertension Canada Clinical Practice Guidelines, and is the Vice Chair of the Pituitary, Gonad, Adrenal and Neuroendocrine Resource Center of the American Association of Clinical Endocrinology.
Dr. Shmouni is the Editor-In-Chief of Endocrine and Metabolic Science (Elsevier), and has authored or co-authored over 100 original articles, reviews and book chapters on neuroendocrine, genetic and metabolic conditions. Dr. Shmouni is enjoys entrepreneurship and early-stage venture work; he co-founded FHS Capital, specialising in early-stage startup consultations and investments, and helps early-stage founders with business strategy and fundraising.
Psychosocial impact on the patient and caregiver.- Transitions of care models.- Genomic endocrinology, genome sequencing, and applications in genetic testing.- Familial endocrine cancer syndromes with pediatric and adolescent presentation.- Familial Thyroid Cancer Syndromes in Children and Adolescents.- Laboratory diagnostics and management of pediatric and adolescent pheochromocytoma and paraganglioma.- Imaging modalities for Pediatric and Adolescent familial cancer syndromes.- Pharmacokinetics and Pharmacodynamics in Adolescents Receiving Cancer Therapies.- Surgical indications for Pediatric and Adolescent familial cancer syndromes: Thyroid Surgery.- Long-Term Effects of Cancer Treatment.- Metabolic Risk and Complications in the Treatment of Pediatric and Adolescent Endocrine Neoplasms.- Fertility in cancer survivors.- Homecare and resources for cancer survivors.
| Erscheinungsdatum | 11.10.2023 |
|---|---|
| Zusatzinfo | X, 227 p. 13 illus., 10 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 571 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie | |
| Schlagworte | Familial endocrine cancer syndrome • Familial medullary thyroid cancer (FMTC) • Hereditary paraganglioma syndrome • Multiple endocrine neoplasia 1 (MEN1) • Multiple endocrine neoplasia 2 (MEN2) • Pharmacogenomics • Pharmacokinetics • Succinate dehydrogenase (SDH) • Von Hippel-Lindau Disease |
| ISBN-10 | 3-031-37274-3 / 3031372743 |
| ISBN-13 | 978-3-031-37274-2 / 9783031372742 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
